Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients

Exclusion Criteria

• •1. Test results showing the following values at screening time(Visit 1)
• •* The change of mean sitSBP ≥ 20 mmHg or sitDBP ≥ 10 mmHg on target arm between 1st and 2nd measurement
• •* screening time(Visit 1), time of randomization(Visit 2): sitDBP ≥ 120 mmHg
• •2. Patients with secondary blood pressure or suspected of secondary blood pressure (for example,aortic coarctation, primary aldosteronism, renal artery stenosis, pheochromocytoma)
• •3. -Patients with congestive heart failure(NYHA class III\~IV)
• •* Patients with unstable angina or myocardial infarction or valvular heart disease within 6 months prior to study entry
• •* Patients who have severe ventricular tachycardia, atrial fibrillation, atrial flutter or clinically significant arrhythmia
• •4. Patients who have history of cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6 months prior to study entry
• •5. Type I Diabets Mellitus or Type II Diabetes Mellitus with HbA1c \> 9%
• •6. Patients who have history of severe or malignant retinopathy within 6 months prior to study entry
• •7. Patients who suspected of Renal dysfunction that may affect the absorption, distribution, metabolism or excretion (Serum Creatinine :\> 2mg/dL ), gastrointestinal, haematological, liver disease (AST or ALT \> 2.5 times of upper limit of normal range)
• •8. Patients who should be administered antihypertensive drugs other than clinical trial medication(Diuretics, β-blockers, ACE inhibitors, Angiotensin II Receptor Blocker, Calcium Channel Blockers, α-blockers, Renin Inhibitors, Vasodilators)
• •9. Patients who should be administered medications prohibited for concomitant use during study period
• •10. Patients who are dependent on drugs or alcohol
• •11. Patients with surgical and medical disease that may affect the absorption, distribution, metabolism or excretion
• •12. Patients with hypersensitivity to the components of investigational drug.
• •13. Patients with hypersensitivity to Sulfonamide
• •14. Patients with anuria
• •15. Patients with hypercalcemia, hyponatremia/hypokalemia
• •16. Patients with Addison's disease
• •17. Patients who have hereditary problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
• •18. Patients with any chronic or accute inflammation disease needed to chronic inflammation therapy
• •19. History of malignant tumor including leukemia, lymphoma within 5 years
• •20. Patients taking other clinical trial drugs within 30 days from the time of visit for screening
• •21. Pregnancy, breast-feeding, or child-bearing potential Patients
• •22. Patients who are judged unsuitable to participate in this study by investigator